Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6811 to 6825 of 8904 results

  1. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  2. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  3. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued Reference number: GID-TA10316

    Technology appraisal guidance
    Discontinued

  4. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    In development Reference number: GID-TA11486 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued Reference number: GID-TA10929

    Technology appraisal guidance
    Discontinued

  6. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued

  7. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued

  8. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  9. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  10. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

    Technology appraisal guidance
    Discontinued

  11. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued Reference number: GID-TA10327

    Technology appraisal guidance
    Discontinued

  12. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued Reference number: GID-TA10309

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

    Technology appraisal guidance
    Discontinued